+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11522(DGKB Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P11522(DGKB Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The DGKB antibody targets diacylglycerol kinase beta (DGKB), an enzyme encoded by the *DGKB* gene, which belongs to the diacylglycerol kinase (DGK) family. DGKB catalyzes the conversion of diacylglycerol (DAG) to phosphatidic acid (PA), a critical step in regulating lipid-mediated signaling pathways. By modulating DAG and PA levels, DGKB influences cellular processes such as membrane trafficking, cell proliferation, and apoptosis. It is particularly abundant in the brain, where it plays a role in neuronal development, synaptic plasticity, and neurotransmitter release, though it is also expressed in immune cells, adipose tissue, and other organs.

DGKB dysfunction has been implicated in metabolic disorders, immune dysregulation, and neurological conditions. Studies link altered DGKB activity to insulin resistance, obesity, and bipolar disorder, highlighting its therapeutic potential. The DGKB antibody is a key tool for investigating these roles, enabling detection and quantification of DGKB protein in tissues or cells via techniques like Western blot, immunohistochemistry, or flow cytometry. Researchers use it to explore DGKB's expression patterns, post-translational modifications, and interactions with signaling molecules. Validated antibodies are essential for specificity, often confirmed through knockout controls or blocking peptides. As interest grows in lipid signaling and metabolic diseases, the DGKB antibody remains vital for elucidating DGKB's physiological and pathological mechanisms.